← Back to Patent Explorer
US5082774A Expired / Lapsed US ⏱️ 0.0 years remaining

Recombinant human nerve growth factor

Assignee: General Hospital Corp
•
Filing: 1988-08-30
•
Granted: 1992-01-21
•
Expires: 2008-08-30
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An expression vector replicable in a mammalian cell includes a prepro-NGF encoding DNA sequence operably linked with regulatory DNA capable of effecting the expression of the prepro-NGF encoding DNA sequence in the cell. Also, a mammalian cell is transfected with such an expression vector. Also, a method for making recombinant human nerve growth factor includes transfecting a mammalian cell with such an expression vector, maintaining the cell in a culture medium, and isolating recombinant human nerve growth factor from the medium. Also, a composition includes recombinant human nerve growth factor made according to such a method combined with a pharmaceutically acceptable carrier.

Inventors

  • 👤 Gerhard Heinrich

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 01:19
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/48; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 66 words
A vector capable of replicating in a mammalian cell, said vector comprising a human prepro-NGF encoding DNA sequence consisting essentially of the coding region of exon 4 of the human NGF gene and regulator DNA operationally associated with and capable of effecting the expression of said human prepro-NGF encoding DNA sequence, said vector being capable of expressing biologically active recombinant human NGF in said mammalian cell.
Claim 2
Dependent Claim 66 words
A vector capable of replicating in a mammalian cell, said vector comprising a human prepro-NGF encoding DNA sequence consisting essentially of the coding region of exon 4 of the human NGF gene and regulator DNA operationally associated with and capable of effecting the expression of said human prepro-NGF encoding DNA sequence, said vector being capable of expressing biologically active recombinant human NGF in said mammalian cell.
Claim 3
Dependent Claim 11 words
A mammalian cell transfected with the expression vector of claim 1.
Claim 4
Dependent Claim 16 words
The mammalian cell of claim 2 wherein said cell is transiently transfected with said expression vector.
Claim 5
Dependent Claim 16 words
The mammalian cell of claim 3 wherein said cell is stably transfected with said expression vector.
Claim 6
Dependent Claim 2 words
Plasmid VP2.
Claim 7
Dependent Claim 2 words
Plasmid VP2.
Claim 8
Dependent Claim 10 words
A mammalian cell transfected with the plasmid of claim 5.
Claim 9
Dependent Claim 11 words
The cell of claim 6, said cell being a COS cell.
Claim 10
Dependent Claim 11 words
The cell of claim 6, said cell being a CHO cell.
Claim 11
Dependent Claim 39 words
A method for making recombinant human nerve growth factor, comprising transfecting a mammalian cell with the expression vector of claim 1, maintaining said mammalian cell in a culture medium, and isolating recombinant human nerve growth factor from said medium.

References Cited (Backward Citations)

EP0121338B1 Cited
US4740461A Cited
US4675285A Cited
US4770999A Cited
US4810643A Cited
WO1988000975A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-01-20 1995-07-22 1996-01-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-01-20 1999-07-22 2000-01-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-01-20 2003-07-22 2004-01-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag